Actively Recruiting
Phase 4 Study Evaluating Safety and Effectiveness of Dapagliflozin or Pioglitazone Added to Metformin and DPP-4 Inhibitor in Adults with Type 2 Diabetes
Led by Dong Wha Pharmaceutical Co. Ltd. · Updated on 2025-03-17
196
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness and safety of adding either Dapagliflozin or Pioglitazone to a treatment plan of Metformin and DPP-4 inhibitors in adults with type 2 diabetes who have not achieved adequate blood sugar control. This Phase 4, multicenter, randomized, open-label, parallel clinical trial aims to gather detailed information on how these additional medications affect diabetes management. The study is sponsored by Dong Wha Pharmaceutical Co. Ltd.
CONDITIONS
Brief Title
DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
